Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

CAMBRIDGE, Mass., Dec. 10 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) approved Cequent's first IND (investigational new drug) application yesterday. This action enables Cequent to initiate the first-ever trial of an orally administered RNA interference drug in humans: CEQ508 - the company's lead drug candidate based on its proprietary tkRNAi technology. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

The IND application acceptance is the second procedural hurdle that the young company has cleared in order to begin human clinical trials of CEQ508 in the FAP (familial adenomatous polyposis) patient population. The company noted that the 14 reviewing members of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) voted unanimously to endorse the proposed clinical protocol after conducting an in-depth review and public discussion of the proposed CEQ508 program on September 9, 2009.*

"We submitted our IND application to the FDA on November 9, 2009. Having our first IND application accepted in the 30-day period is an extraordinary accomplishment for any company, particularly so for Cequent, given that we are working on an entirely new class of drugs," said Cequent Chief Executive Officer Peter Parker. "It speaks volumes to the quality of the submission, which comprised more than 4,000 pages. I'm so proud of our scientific team, who, in a short time, were successful in turning an intriguing RNAi research concept into a viable drug candidate ready to be tested in humans."

The FDA approved Cequent's proposed clinical protocol for the Phase I clinical trial, including
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- The escalation of new biological ... renewed emphasis on alternate delivery technologies. Alternate delivery ... of factors are converging to create both ... delivery device partners . These include new classes ... trend toward self-administration for chronic diseases, shifting patient ...
(Date:5/17/2013)... Inc. (NASDAQ: ATOS ), The Breast Health Company™, ... Financial Officer & General Counsel, will present at the Second ... in New York City at the ... scheduled to begin at 3:30 p.m. EDT and will be ... to www.atossagenetics.com . For more information and ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
(Date:5/19/2013)... (PRWEB) May 20, 2013 May is ... USA. Although located down under, Platypus Australia, the country's ... commemorated ‘Melanoma Monday’ on May 6th to kick off ... to parents. , With the staggering number of ... led to feverish research to find out what’s causing ...
(Date:5/19/2013)... ATS 2013, PHILADELPHIA ─ Gourmands and foodies everywhere have ... a little peppery zing to both sweet and savory ... shows purified components of the spicy root also may ... , The results of the study will be presented ... characterized by bronchoconstriction, a tightening of the bronchial tubes ...
(Date:5/19/2013)... Omaha, Nebraska is a city of diversity, economic ... of the lowest unemployment rates in the country. Forbes Magazine ... for Business and Careers and it consistently scores high on ... located in the nation and is a strong business leader ... of Editions TV are pleased to announce air ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... move forward in a federal litigation now underway in ... to a Case Management Order dated May 3rd, the ... the Bellwether Nominee Pool to eight cases rather than ... litigation is scheduled for Thursday, May 23rd. (In re: ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Grinding your ... just losing sleep, or annoying your spouse. At the ... by CNY Central (“Snoring and Teeth Grinding Could Be ... of teeth grinding can be hard to prevent. Apparently, ... Americans, and one of its symptoms is a habit ...
Breaking Medicine News(10 mins):Health News:Leading Children’s Sun Protection Swimwear Company Platypus Australia use Skin Cancer Awareness Month to Help Educate Parents 2Health News:Leading Children’s Sun Protection Swimwear Company Platypus Australia use Skin Cancer Awareness Month to Help Educate Parents 3Health News:Ginger compounds may be effective in treating asthma symptoms 2Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3
... relatively simple methods, an ultrasound investigation and a blood test ... can predict survival and future heart failure following acute coronary ... the University of Gothenburg, Sweden. Acute coronary syndromes, such ... common causes of emergency medical care and death in Sweden ...
... Elsevier, a world-leading publisher of scientific, technical, and medical ... of the first issue of Practical Radiation Oncology ... Radiation Oncology (ASTRO). Under the guidance of Editor-in-Chief ... aims to improve the quality of radiation oncology practice. ...
... Lake, N.Y. There is an ongoing battle in the ... -- a race between scientists working to develop a vaccine ... use plague as a weapon. "Governments remain concerned that ... could kill thousands," said Stephen Smiley, a leading plague researcher ...
... with human immunodeficiency virus (HIV) impaired results of ... infected patients dropping off the transplantation wait list. ... survival was not impacted following liver transplantation in ... single center studythe largest to dateare published in ...
... 2011 Sustained exposure to loud workplace noise may affect ... to a new study by Ben-Gurion University of the Negev ... , the study compared the sleep quality of individuals at ... some without. Workers with hearing loss had ...
... behavior is similar to that of a person with brain ... forms of treatment," said Dr. Simone Shamay-Tsoory, who conducted the ... just like patients who have suffered frontal head injury. This ... of Haifa. "Our findings show that people who have psychopathic ...
Cached Medicine News:Health News:Ultrasound and a blood test can increase survival after myocardial infarction 2Health News:New discovery could lead to vaccines for plague and bacterial pneumonias 2Health News:Patients infected with HIV have higher drop-out rate for liver transplantation 2Health News:A psychopath lacks empathy just like a person with frontal head injury 2
... motility testing simpler than ever ... up in seconds and protect ... sensor circumferential, Air-Charged Catheters improve ... For advanced performance made easy, ...
... single-use products to promote safety for your ... catheter reduces cross-contamination and helps protect your ... because cleaning is eliminated, you have more ... water perfused manometric catheters for esophageal, anorectal ...
Anorectal Stylet for LATITUDE® Air-Charged Catheter...
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Medicine Products: